|
| Exchange Received Time 24/04/2018 17:40:01 Exchange Disseminated Time 24/04/2018 17:40:04 Time Taken 00:00:03 | We would like to inform our shareholders through exchanges about the information appeared in media about FDA inspection in our Pashamylaram, Medak unit during Feb 2018.
US FDA during the inspection observed that there are procedures that followed on certain aspects are deficient in nature. Since these observations are procedural in nature, we have already revised our standard operating procedures (SOP's) as a corrective action and trained employees in the new SOP's thus creating new policies for the companies' quality systems and operating systems and submitted documented proofs of all these remedial measures to FDA well in time. |
|
|